Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Share repurchases helped enhance the pharmaceutical giant's results.

Biogen's Earnings Per Share Jumped 19% in Fourth Quarter

On Jan. 30 before the market opened, Biogen Inc. (NASDAQ:BIIB) reported its fourth-quarter and full-year earnings for 2019.

Biogen Reports Strong 4th-Quarter Earnings and Growth Potential

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.

Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter.

Biogen (BIIB) Q4 Earnings & Sales Beat Estimates

Shares of Biogen Inc. BIIB, +0.20% were up 2% after the company beat earnings expectations for the fourth quarter.

Biogen's stock rises 2% on Tecfidera sales

Biogen earnings and sales topped Q4 views. The big biotech company gave generally in-line 2020 guidance.

Biogen Earnings Top Views; Biotech Giant Rises

Biogen (NASDAQ: BIIB) reported adjusted fourth-quarter earnings of $8.34 per share on Thursday, which beat the analyst consensus estimate of $7.92 by 5.3%.

Biogen Reports Q4 Earnings Beat

AbbVie

These stocks offer investors good value and have potential to grow.

2 of the Best Healthcare Stocks to Buy Today

Alexion Pharma

Amgen

Eli Lilly

Vertex Pharmaceuticals

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

bluebird bio

Denali Therapeutics

FibroGen

Gilead Sciences

Nektar Therapeutics

Regeneron Pharmaceuticals

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list.

7 Big Biotech Stocks to Avoid

If there is one group that can produce stock gains regardless of the daily market activities, that would be biotechnology and emerging pharmaceuticals.

Why Biogen Could Become the King of Alzheimer’s Disease Treatment

Allergan

Pfizer

This is already a huge week for earnings, as nearly half of the Dow Jones industrial average is reporting, and roughly 150 companies in the S&P 500 as well.

What to Expect From Pfizer, Biogen and Allergan Earnings Tuesday Morning

Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug trial results and skepticism concerning its approvability, an analyst at Canaccord Genuity sounds upbeat.

Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says

Earnings, products, and valuation make Biogen an attractive stock, but uncertainty about its Alzheimer’s drug spell volatility ahead.

Is Biogen  Stock a Buy?

The FDA’s increase in drug approvals and accommodating attitude may smooth the regulatory path for Biogen’s aducanumab.

2 Reasons to be Optimistic About Biogen’s Alzheimer’s Drug

Biogen's decision to forgo a major deal weighed on its shares in 2019.

Why Biogen Stock Slumped Last Year

Cooper Companies

Maxim Integrated Products

Wednesday's big stock charts highlight 3 stocks looking to break through resistance in a market that looks a bit shaky at the moment.

3 Big Stock Charts for Wednesday: Biogen, Cooper Companies, and Maxim

Ionis Pharma

Worms that were fed probiotics saw a reduction in proteins associated with the disease.

New Research Shows Probiotics Can Help Prevent Parkinson's

Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.

Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M

The early-stage drug is part of Biogen's push into neurological diseases.

Biogen Buys Azheimer's and Parkinson's Drug From Pfizer

Biogen Inc. BIIB, +0.75% said Monday it will buy from Pfizer Inc. PFE, +1.54% a potential treatment for behavioral and neurological symptoms, as a potential treatment for Alzheimer's and Parkinson's, for an upfront payment of $75 million and up to $635 million in potential milestone payments.

Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatments

CAMBRIDGE, Mass., Jan.  13, 2020  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. In particular, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). The purchase will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

Which of these two biotech giants is the better buy in 2020?

Better Buy: Biogen vs. Gilead Sciences

Bristol-Myers

Neurocrine Biosciences

Sarepta Therapeutics

If biotech stocks were red hot at the end of 2019, expect them to be scorching next week.

Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To Expect

Both of these pharma giants have encountered obstacles recently, but which of them is the better buy now?

News for Biogen Stock (BIIB)